Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Humira is a prescription tumor necrosis factor blocker containing adalimumab. It treats several inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and noninfectious uveitis.
read more about humira ...Adalimumab binds specifically to tumor necrosis factor alpha and blocks its interaction with the p55 and p75 cell-surface TNF receptors. TNF-alpha participates in normal immune responses but is elevated in several inflammatory diseases. Blocking TNF-alpha reduces inflammatory signaling involved in these disorders.
Humira has adult and pediatric indications that vary by disease. Pediatric labeling includes polyarticular juvenile idiopathic arthritis and uveitis from age 2, ulcerative colitis from age 5, Crohn disease from age 6, and hidradenitis suppurativa from age 12 under weight-based criteria.
Dosing depends on the condition, age, and body weight. Adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis receive 40 mg subcutaneously every other week. Crohn disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis use indication-specific loading and maintenance schedules.
Humira carries boxed warnings for serious infections and malignancies. Risks include tuberculosis, invasive fungal infection, bacterial sepsis, lymphoma, and other cancers. Other serious concerns include hepatitis B reactivation, demyelinating disease, blood-cell abnormalities, worsening heart failure, hypersensitivity, and autoimmune reactions.
Humira is a TNF blocker containing the monoclonal antibody adalimumab.
The recommended dose is 40 mg by subcutaneous injection every other week.
Yes. Patients are evaluated for active tuberculosis and tested for latent tuberculosis before treatment and periodically during therapy.
Yes. The boxed warnings concern serious infections and malignancies.
Adalimumab. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Adalimumab. Date Accessed October 1, 2026.
Adalimumab. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK557889/. Date Accessed October 1, 2026.
Adalimumab Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a603010.html. Date Accessed October 1, 2026.
DailyMed - HUMIRA (adalimumab) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d. Date Accessed October 1, 2026.
HUMIRA (adalimumab) Prescribing Information. AbbVie. https://www.rxabbvie.com/pdf/humira.pdf. Date Accessed October 1, 2026.